ZYVERSA THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Increase Decrease In Operating Lease Liability of -$8.66 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2024-12-31 was $0.00.
- ZYVERSA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2024-09-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2024-06-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2024-03-31 was -$8.66K.
- ZYVERSA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$8.66K.
- ZYVERSA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$100.10K.
| Period end | Increase Decrease In Operating Lease Liability 1 month | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 11 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | -$8.66K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | -$8.66K 10-Q · filed 2025-11-19 | -$34.35K derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$8.66K 10-Q · filed 2025-08-13 | -$34.35K derived: sum of 3 quarters · filed 2025-08-13 | -$59.63K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$8.66K 10-Q · filed 2025-05-12 | -$34.35K derived: sum of 2 quarters · filed 2025-05-12 | -$59.63K derived: sum of 3 quarters · filed 2025-05-12 | -$84.51K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$25.69K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$50.97K derived: sum of 2 quarters · filed 2025-03-27 | -$75.85K derived: sum of 3 quarters · filed 2025-03-27 | -$100.10K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$25.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$50.16K derived: sum of 2 quarters · filed 2024-11-14 | -$74.41K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$24.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$49.13K 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | -$24.25K 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | -$4.79K 10-K · filed 2024-03-25 | |||||
| 2022-12-12 | -$86.10K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |